Introduction
============

The incidence of hearing loss (HL), as the most common sensory defect in newborns, is about 0.1--0.2% ([@B1]). This disease is a multifactorial disorder, which is caused by environmental, genetic, or a combination of these factors ([@B2]). Genetic factors are the leading etiology of more than 50% of the HL cases ([@B3]). The autosomal recessive inheritance pattern is responsible for more than 80% of non-syndromic hereditary HL (ARNSHL) ([@B4]). According to the literature, more than 60 genes and 100 loci are associated with ARNSHL, the most significant of which are *GJB2*, *SLC26A4*, *MYO15A*, *OTOF*, and *CDH23*, respectively ([@B5]).

The discovery of the disease-causing mutations in each gene in population leads to genetic diagnosis and counseling ([@B6]). Regarding the evidence, mutations in *MYO15A* are known to be some of the common causes of severe to profound ARNSHL ([@B7]). Mutations in this gene cause both pre- and post-lingual forms of progressive HL ([@B4], [@B8]). The role of the *MYO15A* gene in the development of HL was identified in a village of Bengkala, Bali, for the first time ([@B9]).

So far, several studies have demonstrated that a total of 192 recessive variants of *MYO15A*(*DFNB3*) are associated with HL ([@B10]). *MYO15A* is found on chromosome 17p11.2, which contains the *DFNB3* locus consisting of 66 exons that encode the myosin-XV with 3,530 amino acids ([@B4]). Myosin-XV is a member of the superfamily of molecular motors. This protein generates the force that drives the mobility within cells by binding to cytoskeletal actin fibers ([@B11]).

These molecular motors, involved in actin organization in the hair cells of the cochlea, are essential for the maturation of these cells and the formation of stereocilia by delivery of whirlin proteins to its top ([@B12]). Due to the large size of the gene and having many exons, simple techniques for detecting mutations are not compatible with this gene. As a result, the frequency and spectrum of the mutations of this gene in most populations are mostly unknown.

However, scientists detected causative DNA mutations in exons of this large gene by new sequencing methods such as targeted genome capture and massively parallel sequencing techniques ([@B2]). No hotspot region has been reported for this gene as yet; however, most of the mutations have been found in the motor domain of *MYO15A*, which is the most conserved domain located between exons 3 to 24 and is considered as the top priority to check ([@B13]).

So far, many studies have been carried out into the importance and prevalence of mutations in *GJB2* and *SLC26A* genes. Nevertheless, few studies were conducted systematically to investigate the importance of *MYO15A* in the incidence of HL. Few studies were performed to estimate the carrier frequency of the *MYO15A* gene and the prevalence of mutations in this gene as well. Accordingly, the aims of this study were defining these values, showing the mutation rate of this gene in different parts of the world, and signing common or founder effects of ethnic groups if they exist.

Materials and Methods
=====================

***Search strategy***

We conducted a literature search in PubMed, Web of Science, Excerpta Medica Database, and Scopus for the English language studies published before September 2019. The search was based on the set of items provided by the Preferred Reporting Item for Systematic Review And Meta-Analysis (PRISMA) statement and was performed by two authors (M.F and M.A). This study is a systematic review of all publications of HL due to *MYO15A* gene mutations. The keywords included: ("MYO15A" or "myosin XVa" or "myoXVa" or "DFNB3") and ("hearing impairment" or "hearing loss" or "deafness"). Moreover, all the citations of the retrieved articles were checked out to recognize additional potential data sources.

***Inclusion criteria***

Two independent reviewers read the titles and abstracts of the retrieved articles and chose those had reported the prevalence of mutations in the *MYO15A* gene or adequate information for calculating the frequency. Disagreements were resolved by consensus discussions; when the debate did not conclude, the disagreement was escalated by the corresponding author.

The inclusion criteria entailed study populations of more than ten patients, the English language, and the examination of the entire length of the*MYO15A* gene to find mutations. Also, review studies and the studies with overlapping data sources or those that were performed on isolated populations were excluded. In case of required information absence, we directly contacted with the corresponding author to request information. In the case of the lack of response and essential data, the selected study was excluded, too.

***Data extraction and quality assessment***

The characteristics were gathered for each study included, first author's name, the year of publication, number of subjects in the healthy and deaf groups, number of patients enrolled without *GJB2* mutation, ethnic and origin of the study population, used diagnostic methods, number of patients with *MYO15A* mutations, and frequency of *MYO15A* mutations. The quality of each study was evaluated based on the quality assessment checklist for prevalence studies ([@B14]).

The scale of this instrument ranges from low to high risk. It includes items such as selection bias, blinding method, instrument reliability and validity, data collection methods, non-response rates, and the case definition. According to this checklist, studies with zero to three, four to six, and seven to nine scores are considered as low, moderate, and high risk, respectively.

***Statistical analysis***

The descriptive analysis of data of included studies and their quality control scores are presented in [Table 1](#T1){ref-type="table"}. The data obtained from all included studies were considered to measure the prevalence of *MYO15A* mutation and carrier frequency.

Meta-analysis was conducted with Comprehensive Meta-Analysis software (ver. 2.2.064, Biostat, Englewood, NJ, USA). The populations of several included studies were combinations of healthy individuals and patients; therefore, the subgroups of controlled and non-controlled were defined. The random-effects model of analysis was selected based on the high I^2^ score.

The studies in the controlled group were assessed for the meta-analysis of the carrier frequency. Publication bias in included studies was estimated by the funnel plot and Egger test. The geographic distributions of the patients with this gene mutation were demonstrated on the map; moreover, the regional prevalence of *MYO15A* mutations in patients with HL was calculated ([Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}).

Results
=======

***Included studies***

In the preliminary search, 590 records were identified from the selected database sources. After the exclusion of duplicated studies, a total of 234 records were obtained from various database resources and hand-searching journals. Finally, a total of 76 eligible records were selected by reading their titles and abstracts. The full texts of these studies were screened, and their qualities were determined; thereby, 32 records were excluded due to various reasons. Ultimately, 25 controlled and 19 non-controlled studies were considered in this systematic review ([Figure 1](#F1){ref-type="fig"}).

Many studies were performed in Iran and Turkey. The sample number of included studies ranged from 10 to 854 individuals ([@B4], [@B12]). According to the quality assessment tool, 37 and 7 studies obtained low and moderate risk grades, respectively ([Table 1](#T1){ref-type="table"}).

***Meta-analysis of the prevalence of MYO15A mutations among GJB2 negative ARNSHL patients***

The prevalence of *MYO15A* mutations in deaf patients was estimated at 6.2% using 44 case series studies (95% CI: 4.9-7.8, *P*\<0.001; [Figure 2](#F2){ref-type="fig"}). Considering the 20% mutation rate of the *GJB2* gene, the frequency of *MYO15A* mutations was calculated as 4.9% among all patients with ARNSHL. The largest sample size belonged to the Miyagawa study (2015), and Ammar khodja study had the lowest.

There was moderate heterogeneity (I^2^=58%, *P*\<0.001); therefore, the random-effects model was applied to calculate this value. Because of the event rate that is always a positive amount, all of the included records were presented on the right side of the forest plots line.

Shafique study in Pakistan had the highest event rate, and the Miyagawa study (2015) in Japan had the lowest.

***Meta-analysis of the carrier frequency***

All of 25 controlled studies were entered into the carrier frequency analysis that contained 3706 healthy controls (the number of chromosomes was used for analysis due to the recessive inheritance pattern of the disease and considering the healthy carriers as the subjects of analysis) ([Figure 2](#F2){ref-type="fig"}). No heterogeneity was found among our studies (I^2^=0%, *P*=0.75).

Meta-analysis of the data demonstrated a carrier frequency of 0.4% (CI95%=0.3-0.6, *P*\<0.001). Woo's study had the highest number of controls, and the study conducted by Diaz-Horta had the lowest. In many studies, no mutation was detected in controls; therefore, most of the included records were presented in forest plots zero line.

***Meta-analysis of overall data***

For calculating the overall prevalence of *MYO15A* gene mutations, all controls and cases of 44 included studies were considered. Because of the heterogeneity of higher than 75%, the random-effects model was applied to analyze overall prevalence. A total of 7882 cases and controls were entered into the analysis, and the overall incidence was calculated as 3.6% (CI: 3.3-3.9, *P*\<0.001; [Figure 2](#F2){ref-type="fig"}). As shown in [Figure 2](#F2){ref-type="fig"}, Chen 2018 study demonstrated the highest frequency.

The Egger test and funnel plot analyzed the possibility of the publication bias in the included articles. According to the distribution of studies in [Figure 3](#F3){ref-type="fig"}, the funnel plot is almost symmetrical. The Egger regression intercept was 0.063 (*P-value*=0.44). As a result, no significant publication bias was found in studies included in this meta-analysis.

To determine the importance of this gene mutation in the development of HL in different parts of the world, the pooled frequency of *MYO15A* mutations was calculated for all countries, where data were available ([Figure 4](#F4){ref-type="fig"}[and]{.ul}[Table 2](#T2){ref-type="table"}). The frequency rates varied from zero to more than 25% based on the included articles; for instance, in a study conducted in Turkey and two experiments in Iran, no mutation was found in the *MYO15A* gene ([@B9], [@B15], [@B16]).

![Preferred reporting items for systematic reviews and meta-analysis study selection flowchart](IJBMS-23-841-g001){#F1}

###### 

Characteristics of included studies in the meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------
                                                                      ()    \     *GJB2*   *Myo15a* (%)\#                          \*         
                                                                            ()                                                                
  ----------- ------ ------------------------------------------------ ----- ----- -------- ---------------- ---------------------- ---------- --
  ([@B34])    2001   Pakistan                                         100   112             9.8             Linkage analysis       Moderate   

  ([@B35])    2007   Turkey                                           115   41    41       4.8              Homozygosity mapping   Low        

  ([@B25])    2007   India, Pakistan, and Turkey                            600   600       3.3             Linkage analysis       Moderate   

  ([@B36])    2009   Iran                                                   40     34      5.8              Linkage analysis       Low        

  ([@B37])    2009   Tunisia                                          50    77    77       3.9              Linkage analysis       Moderate   

  ([@B31])    2010   Turkey                                           100   104   104      9.6              Autozygosity mapping   Low        

  ([@B38])    2010   Palestine                                        288   20    20       10               homozygosity mapping   Low        

  ([@B30])    2011   Turkey                                           100   49    49       9.9              Autozygosity mapping   Low        

  ([@B23])    2011   Israel, Palestine                                240   11    11       18.1             NGS\*\*\*              Low        

  ([@B16])    2011   Iran                                                   37    31       0                Homozygosity mapping   Low        

  -([@B39])   2012   Turkey and Iran                                  15    20    20       15               WES                    Low        

  ([@B40])    2012   Iran                                             100   140   140      5.7              Linkage analysis       Low        

  ([@B26])    2013   Japan                                            144   98    68       8                NGS                    Low        

  ([@B41])    2013   Korea                                            409   13    13       15.3             WES                    Low        

  ([@B24])    2013   China                                            200   117   117       4.2             NGS                    Low        

  ([@B42])    2014   Israel, Palestine                                700   96    96        2               NGS                    Low        

  ([@B43])    2014   Pakistan                                         89    30    14       28               Homozygosity mapping   Low        

  ([@B44])    2014   Germany                                          9     23    14       7                NGS                    Low        

  ([@B45])    2015   Turkey                                                 29     22      4.5              NGS                    Low        

  ([@B4])     2015   Japan                                            269   854            1.1              NGS                    Low        

  ([@B46])    2015   China                                            100   63    63       3.1              NGS                    Moderate   

  -([@B29])   2015   Iran                                                   302    302     9.6              NGS                    Low        

  ([@B47])    2015   Algeria                                          200   65    10       10               WES\*\*                Low        

  ([@B48])    2016   Iran                                                   25     25      4                Linkage analysis       Low        

  ([@B8])     2016   Turkey, Iran, Mexico, Ecuador, and Puerto Rico         160    160     7.5              WES                    Low        

  ([@B48])    2016   Iran                                                   25     25      4                Linkage analysis       Low        

  ([@B2])     2016   South Africa, Nigeria, USA, Tunisia, India,\     200   342   342       2               NGS                    Low        
                     Iran, Turkey, and Guatemala                                                                                              

  ([@B22])    2016   Western Europe                                   6     131   131      3                NGS                    Low        

  ([@B9])     2016   Iran                                                   16     14      0                Linkage analysis       Low        

  ([@B12])    2016   Iran                                             100   30             3.3              Linkage analysis       Moderate   

  ([@B49])    2017   Japan                                            200   143   143      4                NGS                    Low        

  ([@B50])    2017   Korea                                            32    28    25       8                WES                    Low        

  ([@B51])    2017   Morocco                                                33    33       3                WES                    Moderate   

  ([@B52])    2017   China                                                  207   152      2.5              NGS                    Low        

  ([@B53])    2018   Spain                                                  50    50       2.2              NGS                    Low        

  ([@B54])    2018   China                                                  18    12       25               NGS                    Low        

  ([@B55])    2018   Israel                                           110   47    13       15.3             NGS                    Low        

  ([@B56])    2018   USA                                                    33    23       4.3              NGS                    Moderate   

  ([@B57])    2018   China                                                  44    28       10.7             NGS                    Low        

  ([@B58])    2019   Vietnam                                          117   87    55       7.2              NGS                    Low        

  ([@B59])    2019   Pakistan                                         200   40    25       8                NGS                    Low        

  ([@B60])    2019   Taiwan                                           128   41    41       4.8              NGS                    Low        

  ([@B61])    2019   Iran                                                   28    28       10.7             WES                    Low        

  ([@B62])    2019   china                                            200   33    26       7.6              WES                    Low        
  ----------------------------------------------------------------------------------------------------------------------------------------------

\*Quality assessment was done by the quality assessment checklist for prevalence studies, \*\*Whole-exome sequencing, \*\*\*Next-generation sequencing, \# The frequency of MYO15A mutations is achieved through dividing the number of patients with MYO15A mutation by the number of all nonsyndromic GJB2 negative patients

###### 

The regional prevalence of *MYO15A* mutations in GJB2 negative ARNSHL patients

  Country         Frequency of MYO15A mutations (%)
  --------------- -----------------------------------
  Brazil          52
  Oman            30
  Korea           10.5
  Algeria         10
  Mexico          7.5
  Puerto Rico     7.5
  Vietnam         7.2
  Germany         7.1
  Iran            5.8
  Banglaka        5
  Pakistan        4.9
  Taiwan          4.8
  Palestin        4.7
  China           4.7
  Turkey          4.4
  United States   3.8
  Israel          3.7
  India           3.6
  Europe          3.1
  Moroccan        3
  Tunisia         2.3
  Spain           2.2
  South Africa    2
  Nigeria         2
  Guatemala       2
  Japan           2

![Forest plots of meta-analysis on the *MYO15A* mutation frequency using the random-effects model by Comprehensive Meta-Analysis software. a) The *MYO15A* mutation frequency among patients with autosomal-recessive non-syndromic hearing loss, who were GJB2 negative. All of the included studies had the same direction in this plot. The bars indicate 95% CI frequency of *MYO15A* mutations. I^2^=56%, *P*\<0.001. The middle of the diamond shows the total prevalence. b) Forest plots of the overall prevalence of *MYO15A* mutation among all cases and controls. Chen's study had the highest event rate. c) Forest plots on MYO15A carrier frequency in healthy controls. The number of controls in Diaz-Horta's study was the lowest among 25 controlled studies; therefore, its CI95% was the widest. Moreover, no heterogeneity was found (I^2^=0%, *P*=0.75)](IJBMS-23-841-g002){#F2}

![Funnel plots of included studies in meta-analysis to evaluate publication bias. Each hollow point represents a single study. The horizontal line displays natural logarithm of event rate](IJBMS-23-841-g003){#F3}

![Geographical distribution of *MYO15A* mutations in patients with the autosomal recessive non-syndromic hearing loss who were GJB2 negative. The pooled frequency of *MYO15A* mutations was calculated for all countries, where data were available. Brazil and Oman had the highest rate of *MYO15A* mutation compared to other areas. Japan, Guatemala, Nigeria, and South Africa had a minimum of 2% mutation frequency](IJBMS-23-841-g004){#F4}

Discussion
==========

According to the results of this meta-analysis of data from [44]{.ul} studies conducted among [4176]{.ul} GJB2 negative patients suffering from HL, there was a pooled global frequency of *MYO15A* mutation rate of [6.2%]{.ul}**[,]{.ul}** that represents a prominent role for this gene mutation in hereditary HL. Nowadays, routine screening of *MYO15A* mutation is not performed in deaf patients due to its large size and having many exons (66 exons) ([@B17]). Also, methods like whole-exome sequencing, linkage analysis, and homozygosity mapping in consanguineous families were performed to detect *MYO15A* mutations, which are expensive, and this is a barrier to implementing them.

To the best of our knowledge, so far, few studies have synthesized the *MYO15A* mutation data in patients with ARNSHL worldwide. Nevertheless, in several studies, this gene was introduced as the second most crucial gene after *GJB2* as a cause of HL ([@B2], [@B8], [@B10], [@B18]).

Many studies assayed the prevalence of mutations in the *GJB2* and *SLC26A4* genes among patients with ARNSHL in different parts of the world. They demonstrated that the prevalences of mutations in GJB2 and *SLC26A4* are about 15% to 25% and 2% to 12.6%, respectively, which are dependent on the region ([@B19]). Therefore, *MYO15A* is the third most important gene contributing to ARNSHL. Additionally, the frequency of *MYO15A* mutation is higher than *SLC26A4* mutations in several regions and has priority.

Except for the frequency of common founder mutations in Brazil and Oman, *MYO15A* mutation frequencies in Algeria and Korea were higher in comparison to other areas (10%). Japan, Guatemala, Nigeria, and South Africa had the same minimum of 2% mutation frequency ([Figure 4](#F4){ref-type="fig"}). A broad spectrum of *MYO15A* mutation was discovered around the world, 68.62% of which are missense mutations ([@B20]). Moreover, most of these mutations were reported in studies as novel variants, and only some were repeated in a few studies. For example, c.7395+3G\>C was identified in Tunisian patients in two studies ([@B21], [@B22]) and 8183G\>A was discovered in patients from three different countries, namely, China, Brazil, and Israel ([@B18], [@B23], [@B24]). In addition, 9478C\>T was observed in Japanese patients in two studies and one Pakistani patient ([@B4], [@B25], [@B26]).

There are several founder haplotypes in *MYO15A* that are specific to a particular geographic zone, similar to *Val1400Met* (c.4198G\>A) variation, which is found in about 50% of patients with ARNSHL in a region of Brazil and Turkey due to endogamous nature of these regions ([@B18], [@B27]). The haplotypes associated with *Val1400Met* in Brazil were different from those in Turkey. Additionally, in Oman, 30% of patients had a specific duplication mutation (c.1171_1177dupGCCATCT) ([@B28]). Two founder mutations, including p.Tyr1392Stop and p.D2720H (c.8158G4C) were reported in Iran and Pakistan, respectively ([@B25], [@B29]). Two variants of p.R1937TfsX10 (c.5809C\>T) and p.S3335AfsX121 (c.9995_10002dup) were probably founder haplotypes in Turkey ([@B27]).

The presence of these founder mutations in isolated populations might be useful to create a population screening for hereditary HL. Genotype-phenotype correlation between mutated region and severity of HL was reported in this gene.*MYO15A* gene mutations often cause severe to profound HL; nevertheless, the severity of deafness is moderate to severe only in patients with mutations in exon 2 ([@B2], [@B21], [@B25], [@B30]-[@B33]).

These observations may reflect the presence of modifier factors. Most mutations in exon two were reported in the Middle East, such as Turkey, Iran, Pakistan, and Palestine. As a result, examining the second exon of *MYO15A* in patients in the Middle East, as well as patients with milder HL had the priority ([@B63]).

Several points should be considered in interpreting the results of our study. First, there is heterogeneity between the results of different studies due to using various mutation detection methods. Some methods are not able to identify all existing mutations. As a result, the prevalence of mutation may be underestimated. On the other hand, non-pathogenic variants discovered in patients with HL may be incorrectly considered mutations.

*MYO15A* mutations cause the autosomal recessive form of HL; therefore, we extracted the exact number of autosomal recessive patients that did not have any *GJB2* mutations from each article and compared the frequency between them. In several studies, this number was not reported; accordingly, we omitted them from the analysis due to the lack of sufficient information.

***Strengths and limitations of this study***

In the current study, only published studies were included, while those with negative results might be unpublished. Additionally, missing several relevant articles in the search process is possible. This study has several strengths, too. We used a manual search to have a comprehensive search strategy as much as possible. Heterogeneity was not observed in studies, which indicates the power of this study.

Therefore, it is recommended for researchers to report their results clearly to simplify further meta-analysis. For instance, reporting the inheritance of HL or the number of patients with mutations in each gene is essential.

In most patients with ARNSHL, the *GJB2* gene was checked to identify the genetic causes of HL for only one exon. Although the genetic cause of deafness in many patients were a mutation in other genes, and due to the high cost of conventional sequencing methods, the genetic cause of the disease remains unknown in these individuals.

Conclusion
==========

Based on the results of this the meta-analysis, after the examination of *GJB2* and *SLC26A4* in the patients with HL, checking the*MYO15A* gene is of paramount importance. Due to the large size of this gene, paying particular attention to geographic region is suggested, so as to perform the diagnostic tests properly. Moreover, if there is a dominant mutation in the region, initial assessment for the mutation will be recommended.

Otherwise, the preferred regions are the motor domain and sometimes the second exon of this gene. Accordingly, further studies considering the detailed data about the mutations, particularly in combination with the assessment of the other gene mutations to clarify the exact roles of the mutations in HL and the affected genes are recommended.
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